Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 14/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.58 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.58 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.55 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938492 | 0.98 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL13207179 | 0.94 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL12801726 | 0.86 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL10075487 | 0.83 | POLB (0.58) | L3MBTL3L3MBTL1EPHX2EPHX1KDM4E | |
| SCHEMBL13453747 | 0.83 | POLB (0.58) | L3MBTL3L3MBTL1EPHX2EPHX1KDM4E | |
| SCHEMBL13088457 | 0.83 | POLB (0.58) | L3MBTL3L3MBTL1EPHX2EPHX1KDM4E | |
| SCHEMBL19630972 | 0.83 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL6806463 | 0.83 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL920191 | 0.83 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL25628643 | 0.82 | USP2 (0.43) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023102472-A1 | ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230159480-A1 | SYNTHESIS OF ESUBERAPROST PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159480-A1 | SYNTHESIS OF ESUBERAPROST PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-11560363-B2 | Synthesis of esuberaprost prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210355095-A1 | SYNTHESIS OF ESUBERAPROST PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2021-11-18 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3371192-B1 | PODOPHYLLOTOXIN DERIVATIVES AND THEIR USE | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190224220-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | ABBVIE INC. (US) | 2019-07-25 | — | — | US | disclosed |
| EP-2097097-B1 | ANTIBODIES, IN PARTICULAR HUMAN ANTIBODIES, THAT BIND CD22 AND USES THEREOF | SQUIBB & SONS LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-20070254915-A1 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070135346-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
| US-7202239-B2 | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | L3MBTL3 2148/4885L3MBTL1 1804/4885MBTD1 1780/4885 |
| US-11560363-B2 | Synthesis of esuberaprost prodrugs | DCPS, DNPEP, NPEPPS | L3MBTL3 2608/4885L3MBTL1 2044/4885MBTD1 3154/4885 |
| US-20230159480-A1 | SYNTHESIS OF ESUBERAPROST PRODRUGS | DCPS, DNPEP, NPEPPS | L3MBTL3 2608/4885L3MBTL1 2044/4885MBTD1 3154/4885 |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | ERCC2, CHEK1, ERCC4 | L3MBTL3 1559/4885L3MBTL1 1052/4885MBTD1 902/4885 |
| US-20210355095-A1 | SYNTHESIS OF ESUBERAPROST PRODRUGS | DCPS, DNPEP, NPEPPS | L3MBTL3 2608/4885L3MBTL1 2044/4885MBTD1 3154/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | L3MBTL3 1122/4885L3MBTL1 2503/4885MBTD1 3134/4885 |
| US-20190224220-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | COMT, SNCA, PARK7 | L3MBTL3 768/4885L3MBTL1 563/4885MBTD1 3275/4885 |
| US-20070254915-A1 | CXCR4 MODULATORS | CXCL12, CXCR4, CXCR1 | L3MBTL3 3355/4885L3MBTL1 2170/4885MBTD1 943/4885 |
| US-20070135346-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | L3MBTL3 2653/4885L3MBTL1 2095/4885MBTD1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.